What are the regulations for prescribing schedule II stimulants for a 90‑day supply?

Regulations for 90-Day Stimulant Prescriptions

Schedule II stimulants can be prescribed for a 90-day supply through the DEA's "prescription series" regulation, which allows practitioners to issue multiple same-day prescriptions for Schedule II controlled substances to be dispensed sequentially (e.g., three 30-day prescriptions dated for sequential monthly fills). This practice is explicitly legal under current federal DEA regulations 1, 2.

Key Regulatory Framework

Federal DEA Requirements

The DEA regulation specifically authorizes writing multiple prescriptions on the same day for Schedule II medications, addressing the dual goals of preventing diversion while maintaining legitimate patient access 1. This represents a policy shift that allows:

• Multiple prescriptions written simultaneously but dated for sequential dispensing (e.g., one prescription for immediate fill, two additional prescriptions post-dated for 30 and 60 days later)
• No arbitrary quantity limits imposed by the regulation itself—the DEA explicitly confirmed they did not intend to restrict appropriate prescribing practices 1
• Continuous medication access for stabilized patients without requiring monthly office visits 2

Critical Implementation Requirements

When prescribing stimulants for extended periods, you must:

• Document medical necessity clearly in the patient record, particularly if using higher doses or extended supplies
• Ensure each prescription includes: "Do not fill until [specific date]" on the post-dated prescriptions
• Verify no contraindications exist, including active psychosis, current MAO inhibitor use, uncontrolled hypertension, or active stimulant abuse (unless in a controlled/supervised setting) 3

Monitoring Requirements for Extended Prescriptions

Baseline and Ongoing Assessment

Before initiating any extended prescription series 3:

• Physical examination with baseline blood pressure, pulse, height, and weight
• Documentation of prior treatments and medication trials
• Assessment for contraindications (cardiovascular disease, hyperthyroidism, glaucoma, psychosis)

Maintenance Phase Monitoring

For patients on stable doses receiving 90-day supplies 3:

• Children/adolescents: Vital signs checked annually during routine physical examination
• Adults: Blood pressure and pulse checked quarterly by treating or primary care physician
• All patients: Monthly follow-up appointments until symptoms stabilized, then frequency determined by response robustness, adherence, side effects, and comorbidities 3

Safety Considerations and Risk Mitigation

Patient Selection

Exercise extreme caution with 90-day prescriptions in patients with:

• Suicide risk: The rise of 90-day prescriptions creates significant safety concerns for patients at risk for intentional overdose 4
• Substance use history: While not an absolute contraindication, requires enhanced monitoring 3, 5
• Household members with stimulant abuse history: Implement safeguards to prevent diversion 3

Patient Agreement Implementation

Consider implementing a Schedule II controlled substance patient agreement 5, which has demonstrated:

• 94% compliance with signed agreements
• 71.1% adherence to urine screening (up from 5.3%)
• 99.0% adherence to prescription monitoring program checks (up from 11.3%)
• Elimination of prescriptions written without mandatory visits

Common Pitfalls to Avoid

1. Insurance/pharmacy interference: Some insurers now require prior authorization for 30-day prescriptions while incentivizing 90-day supplies, and some pharmacists can unilaterally convert prescriptions—this may conflict with clinical judgment for at-risk patients 4

2. Inadequate documentation: When prescribing extended supplies, clearly document that symptoms cannot be controlled at lower doses and that higher doses produce no concerning side effects 3

3. Missed monitoring: The convenience of 90-day prescriptions should not eliminate the need for regular clinical assessment, particularly for blood pressure, weight, and symptom control 3

4. Failure to assess diversion risk: Before writing multiple prescriptions, evaluate household risk factors and patient reliability 3

The key is balancing legitimate patient access and convenience against safety concerns—use clinical judgment to determine which patients are appropriate candidates for extended prescription series versus those requiring monthly prescribing and visits.